NASDAQ:SPRO

Spero Therapeutics (SPRO) Stock Price, News & Analysis

Spero Therapeutics logo
$0.88 -0.02 (-2.03%)
As of 03:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Spero Therapeutics Stock (NASDAQ:SPRO)

Advanced

Key Stats

Today's Range
$0.87
▼
$0.95
50-Day Range
$0.90
▼
$1.36
52-Week Range
$0.87
▼
$3.08
Volume
241,502 shs
Average Volume
770,017 shs
Market Capitalization
$51.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and difficult-to-treat bacterial infections. Its work has centered on antibiotic candidates intended to address infections for which existing treatment options may be limited.

The company’s pipeline has included tebipenem HBr, an oral antibiotic candidate studied for complicated urinary tract infections, and programs targeting drug-resistant Gram-negative bacteria and nontuberculous mycobacterial infections. Spero has also pursued development and commercialization partnerships, including a collaboration with GSK on tebipenem.

Based in Cambridge, Massachusetts, Spero has conducted its development activities primarily through research, clinical testing and partnerships. Its programs and development plans may change as clinical results and regulatory reviews evolve.

AI Generated. May Contain Errors.

Spero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

SPRO MarketRank™: 
3.82505313496 of 5 stars

Spero Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 71st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spero Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    Spero Therapeutics has a consensus price target of $6.00, representing about 576.4% upside from its current price of $0.89.

  • Amount of Analyst Coverage

    Spero Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Spero Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Spero Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.93) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spero Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spero Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spero Therapeutics has a P/B Ratio of 88.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.39% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 2.23, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently decreased by 6.37%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Spero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Spero Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Spero Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Spero Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    3 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,485.00 in company stock.

  • Percentage Held by Insiders

    2.90% of the stock of Spero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    25.60% of the stock of Spero Therapeutics is held by institutions.

  • Read more about Spero Therapeutics' insider trading history.
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SPRO Stock News Headlines

Spero Therapeutics (NASDAQ:SPRO) Cut to "Strong Sell" at Wall Street Zen
Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Spero Therapeutics, Inc. Announces Board and Committee Changes
See More Headlines

SPRO Stock Analysis - Frequently Asked Questions

Spero Therapeutics' stock was trading at $2.33 at the beginning of the year. Since then, SPRO stock has decreased by 61.9% and is now trading at $0.8870.

Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings data on Thursday, November, 12th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.29. Spero Therapeutics had a trailing twelve-month return on equity of 13.98% and a net margin of 24.90%.

Spero Therapeutics (SPRO) raised $82 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,500,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Top institutional investors of Spero Therapeutics include State Street Corp (0.43%), Marshall Wace LLP (0.34%) and Empowered Funds LLC (0.11%). Insiders that own company stock include Sath Shukla, Esther Rajavelu, Ankit Mahadevia and Timothy Keutzer.
View institutional ownership trends
.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Editas Medicine (EDIT), Aktis Oncology (AKTS), Heron Therapeutics (HRTX), Nokia (NOK), Arcturus Therapeutics (ARCT), Corning (GLW) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SPRO
CIK
1701108
Fax
N/A
Employees
25
Year Founded
2013

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Potential Upside/Downside
+580.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$8.57 million
Net Margins
24.90%
Pretax Margin
-70.39%
Return on Equity
13.98%
Return on Assets
7.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.92
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$66.80 million
Price / Sales
0.77
Cash Flow
$0.14 per share
Price / Cash Flow
6.22
Book Value
$0.01 per share
Price / Book
88.20

Miscellaneous

Outstanding Shares
58,260,000
Free Float
56,546,000
Market Cap
$51.39 million
Optionable
Optionable
Beta
1.59

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:SPRO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners